Bolt Biotherapeutics Inc (NASDAQ: BOLT) is -39.50% lower on its value in year-to-date trading and has touched a low of $0.65 and a high of $1.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BOLT stock was last observed hovering at around $0.69 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.68, the stock is -2.82% and -6.02% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.14 million and changing -1.78% at the moment leaves the stock -30.64% off its SMA200. BOLT registered -40.04% loss for a year compared to 6-month loss of -44.00%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.81% gain in the last 1 month and extending the period to 3 months gives it a -10.45%, and is -1.45% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.33% over the week and 3.36% over the month.
Bolt Biotherapeutics Inc (BOLT) has around 100 employees, a market worth around $25.92M and $11.17M in sales. Profit margin for the company is -592.57%. Distance from 52-week low is 4.25% and -56.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.02%).
The EPS is expected to grow by 20.22% this year.
Bolt Biotherapeutics Inc (BOLT) Top Institutional Holders
43.0 institutions hold shares in Bolt Biotherapeutics Inc (BOLT), with institutional investors hold 62.52% of the company’s shares. The shares outstanding are 38.11M, and float is at 25.77M with Short Float at 0.94%. Institutions hold 60.36% of the Float.
The top institutional shareholder in the company is TANG CAPITAL MANAGEMENT LLC with over 3.81 million shares valued at $2.86 million. The investor’s holdings represent 10.0156% of the BOLT Shares outstanding. As of 2024-06-30, the second largest holder is VIVO CAPITAL, LLC with 3.52 million shares valued at $$2.64 million to account for 9.2499 of the shares outstanding. The other top investors are SOFINNOVA INVESTMENTS, INC. which holds 2.75 million shares representing 7.2355% and valued at over $2.07 million, while CITADEL ADVISORS LLC holds 6.2191 of the shares totaling 2.37 million with a market value of $1.78 million.
Bolt Biotherapeutics Inc (BOLT) Insider Activity
The most recent transaction is an insider purchase by Quinn William P.,the company’sChief Financial Officer. SEC filings show that Quinn William P. bought 7,500 shares of the company’s common stock on Dec 12 ’23 at a price of $0.95 per share for a total of $7125.0. Following the purchase, the insider now owns 36272.0 shares.
Bolt Biotherapeutics Inc disclosed in a document filed with the SEC on Dec 06 ’23 that Quinn William P. (Chief Financial Officer) bought a total of 2,500 shares of the company’s common stock. The trade occurred on Dec 06 ’23 and was made at $0.78 per share for $1955.0. Following the transaction, the insider now directly holds 28772.0 shares of the BOLT stock.
Still, SEC filings show that on Nov 30 ’23, ENGLEMAN EDGAR (Director) disposed off 123,079 shares at an average price of $0.86 for $0.11 million. The insider now directly holds 251,522 shares of Bolt Biotherapeutics Inc (BOLT).
